Company Profile
OKYO Pharma Stock Price, News & Catalysts
- Ticker:
- OKYO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.46 USD (-0.68%)
Close
Last updated: October 6, 2026
89.2M USD
Market cap
Why the stock is moving
The latest company update was “OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain”. OKYO changed 0.68% and closed at $1.46 on Oct 6, 2026, indicating a relatively limited closing-price reaction to this clinical readout update.
Company overview
Ocular Pain Drug Developer
OKYO Pharma develops therapies for inflammatory and neuropathic eye diseases. Its lead program targets chronic corneal pain, a condition with no specifically approved pharmacologic treatment.
Urcosimod Lead Candidate
Urcosimod, formerly OK-101, is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor. The molecule is designed for topical ocular delivery and aims to provide anti-inflammatory and pain-modulating effects.
Neuropathic Corneal Pain Program
The company completed a Phase 2 study in neuropathic corneal pain that showed improvements in pain measures and supported advancement into pivotal development. The planned program targets patients with persistent symptoms despite conventional ocular-surface treatments.
Dry Eye Clinical Experience
Urcosimod has also been evaluated in dry eye disease, providing human safety and dosing experience across a broader ocular-surface population. Those data inform formulation and clinical execution for the pain indication.
Topical Ophthalmology Model
OKYO retains a focused development organization and uses external manufacturers, clinical sites, and research partners. Its strategy is to advance a differentiated topical medicine through late-stage trials and regulatory review.
Future catalysts
- Initiation of the global Phase 3 NEPTUNE trial of urcosimod in neuropathic corneal pain in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of OKYO Pharma (OKYO)?
OKYO Pharma (OKYO) most recently closed at 1.46 USD, a -0.68% move versus the previous session.
What is the market cap of OKYO Pharma (OKYO)?
OKYO Pharma currently has a market capitalization of 89.2M USD on BioPharmSignal.
What does OKYO Pharma do?
Ocular Pain Drug Developer OKYO Pharma develops therapies for inflammatory and neuropathic eye diseases. Its lead program targets chronic corneal pain, a condition with no specifically approved pharmacologic treatment. Urcosimod Lead Candidate Urcosimod, formerly OK-101, is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor. The molecule is...
On which exchange is OKYO stock listed?
OKYO Pharma (OKYO) is associated with NASDAQ, United States, Biopharma.
What is OK-101?
Urcosimod Lead Candidate Urcosimod, formerly OK-101, is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor.
Which conditions is OKYO Pharma targeting with OK-101?
OKYO Pharma is associated with ophthalmology based on its company overview and current catalyst commentary.
How does OKYO Pharma describe recent progress with OK-101?
Initiation of the global Phase 3 NEPTUNE trial of urcosimod in neuropathic corneal pain in the second half of 2026.
What is Ocular?
Ocular Pain Drug Developer OKYO Pharma develops therapies for inflammatory and neuropathic eye diseases.